8-K: Predictive Oncology Receives Nasdaq Delisting Warning Due to Sub-$1.00 Share Price

Predictive Oncology Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, triggering a 180-day period to regain compliance.

Summary

• Predictive Oncology Inc. received a letter from The Nasdaq Stock Market LLC on July 8, 2025, indicating non-compliance with Nasdaq Marketplace Rule 5550(a)(2).
• The non-compliance stems from the company's common stock bid price closing below $1.00 per share for 30 consecutive business days.
• This notification does not have an immediate effect on the listing of the company's common stock.
• The company has a period of 180 calendar days, until January 5, 2026, to regain compliance with the Minimum Bid Price Requirement.
• Compliance can be regained if the bid price of the common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days.
• If compliance is not regained by January 5, 2026, the company may be eligible for additional time if it meets other continued listing requirements and provides written notice of its intention to cure the deficiency, potentially by effecting a reverse stock split.
• Failure to cure the deficiency or qualify for an extension could lead to notification of delisting, which the company may appeal.
• The company intends to actively monitor its common stock's bid price and consider available options to resolve the deficiency.

Sentiment

Score: 3

Explanation: The company received a delisting warning due to its low stock price, indicating significant market underperformance and a risk to its listing status. While there's a compliance period, the underlying issue is negative.

Negatives

• Received a notice of non-compliance from Nasdaq regarding the minimum bid price requirement.
• Common stock bid price closed below $1.00 per share for 30 consecutive business days.
• Faces potential delisting from The Nasdaq Capital Market if compliance is not regained within the specified period.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) by January 5, 2026.
• Potential delisting of common stock from The Nasdaq Capital Market.
• Uncertainty regarding eligibility for an additional compliance period if initial compliance is not met.
• No assurance that Nasdaq will grant a request for continued listing if an appeal is made.
• Actual results could differ materially from forward-looking statements due to inherent risks and uncertainties.

Future Outlook

The company intends to continue actively monitoring the bid price for its common stock and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.

Management Comments

• "The Company intends to continue actively monitoring the bid price for its common stock and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement."

Industry Context

NA

Stakeholder Impact

• Shareholders face the risk of reduced liquidity and potential further decline in stock price if the company fails to regain compliance or is delisted.
• The company's management will need to dedicate resources to addressing the compliance issue and exploring options to regain listing status.

Next Steps

• Regain compliance with Nasdaq's Minimum Bid Price Requirement by January 5, 2026.
• Achieve a closing bid price of $1.00 or more for at least 10 consecutive business days.
• If not compliant by the deadline, potentially qualify for an additional compliance period by meeting other listing standards and providing notice of intent to cure (e.g., reverse stock split).
• Monitor the bid price for common stock.
• Consider available options to resolve the deficiency.
• Potentially appeal a delisting determination if notified of delisting.

Key Dates

Keywords

Predictive Oncology, POAI, Nasdaq, Delisting, Minimum Bid Price, Compliance, Stock Market, 8-K, Biotechnology, Oncology